KalVista Pharmaceuticals Gains on Strong Demand for Genetic-Disorder Treatment

Dow Jones

01/09

By Kelly Cloonan

Shares of KalVista Pharmaceuticals climbed after the company said it saw strong demand for Ekterly, a treatment for a rare genetic disorder, in its latest quarter.

The stock rose 14%, to $17.99, in after-hours trading on Thursday. Through market close, shares have surged 92% in the past 12 months.

Chief Executive Ben Palleiko said the company is extremely pleased with its performance since offering Ekterly, an oral treatment for hereditary angioedema, in July.

"Fundamental demand has remained strong, with some effects from seasonal variability, and we are encouraged by the continued high level of interest in switching to Ekterly," Palleiko said.

The Framingham, Mass., company now expects net product revenue of $35 million for the fourth quarter and $49 million for 2025. Analysts polled by FactSet had expected full-year revenue of $32.7 million.

The company is also seeing strong uptake for Ekterly in Germany, Palleiko said, noting early prescribing behaviors in the country have mirrored the positive trends the company saw in the U.S. The company expects to expand into other major markets this year, he added.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

January 08, 2026 18:53 ET (23:53 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2602319748"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602319748\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602319748?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-09 07:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602319748","market":"sg","top_or_hot":-1,"title":"KalVista Pharmaceuticals Gains on Strong Demand for Genetic-Disorder Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of KalVista Pharmaceuticals climbed after the company said it saw strong demand for Ekterly, a treatment for a rare genetic disorder, in its latest quarter. \n</p>\n<p>\n  The stock rose 14%, to $17.99, in after-hours trading on Thursday. Through market close, shares have surged 92% in the past 12 months. \n</p>\n<p>\n  Chief Executive Ben Palleiko said the company is extremely pleased with its performance since offering Ekterly, an oral treatment for hereditary angioedema, in July. \n</p>\n<p>\n  \"Fundamental demand has remained strong, with some effects from seasonal variability, and we are encouraged by the continued high level of interest in switching to Ekterly,\" Palleiko said. \n</p>\n<p>\n  The Framingham, Mass., company now expects net product revenue of $35 million for the fourth quarter and $49 million for 2025. Analysts polled by FactSet had expected full-year revenue of $32.7 million. \n</p>\n<p>\n  The company is also seeing strong uptake for Ekterly in Germany, Palleiko said, noting early prescribing behaviors in the country have mirrored the positive trends the company saw in the U.S. The company expects to expand into other major markets this year, he added. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2026 18:53 ET (23:53 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>KalVista Pharmaceuticals Gains on Strong Demand for Genetic-Disorder Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKalVista Pharmaceuticals Gains on Strong Demand for Genetic-Disorder Treatment\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-01-09 07:53</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of KalVista Pharmaceuticals climbed after the company said it saw strong demand for Ekterly, a treatment for a rare genetic disorder, in its latest quarter. \n</p>\n<p>\n  The stock rose 14%, to $17.99, in after-hours trading on Thursday. Through market close, shares have surged 92% in the past 12 months. \n</p>\n<p>\n  Chief Executive Ben Palleiko said the company is extremely pleased with its performance since offering Ekterly, an oral treatment for hereditary angioedema, in July. \n</p>\n<p>\n  \"Fundamental demand has remained strong, with some effects from seasonal variability, and we are encouraged by the continued high level of interest in switching to Ekterly,\" Palleiko said. \n</p>\n<p>\n  The Framingham, Mass., company now expects net product revenue of $35 million for the fourth quarter and $49 million for 2025. Analysts polled by FactSet had expected full-year revenue of $32.7 million. \n</p>\n<p>\n  The company is also seeing strong uptake for Ekterly in Germany, Palleiko said, noting early prescribing behaviors in the country have mirrored the positive trends the company saw in the U.S. The company expects to expand into other major markets this year, he added. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2026 18:53 ET (23:53 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2602319748","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602319748","pubTimestamp":1767916380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of KalVista Pharmaceuticals climbed after the company said it saw strong demand for Ekterly, a treatment for a rare genetic disorder, in its latest quarter.The stock rose 14%, to $17.99, in after-hours trading on Thursday. Through market close, shares have surged 92% in the past 12 months.Chief Executive Ben Palleiko said the company is extremely pleased with its performance since offering Ekterly, an oral treatment for hereditary angioedema, in July.\"Fundamental demand has remained strong, with some effects from seasonal variability, and we are encouraged by the continued high level of interest in switching to Ekterly,\" Palleiko said.The Framingham, Mass., company now expects net product revenue of $35 million for the fourth quarter and $49 million for 2025. Analysts polled by FactSet had expected full-year revenue of $32.7 million.The company is also seeing strong uptake for Ekterly in Germany, Palleiko said, noting early prescribing behaviors in the country have mirrored the ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","KALV":"Kalvista Pharmaceuticals Inc"},"translate_title":"KalVista Pharmaceuticals因遗传疾病治疗的强劲需求而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KALV":0.9},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Shares of KalVista Pharmaceuticals climbed after the company said it saw strong demand for Ekterly, a treatment for a rare genetic disorder, in its latest quarter. \n\n\n  The stock rose 14%, to $17.99, in after-hours trading on Thursday. Through market close, shares have surged 92% in the past 12 months. \n\n\n  Chief Executive Ben Palleiko said the company is extremely pleased with its performance since offering Ekterly, an oral treatment for hereditary angioedema, in July. \n\n\n  \"Fundamental demand has remained strong, with some effects from seasonal variability, and we are encouraged by the continued high level of interest in switching to Ekterly,\" Palleiko said. \n\n\n  The Framingham, Mass., company now expects net product revenue of $35 million for the fourth quarter and $49 million for 2025. Analysts polled by FactSet had expected full-year revenue of $32.7 million. \n\n\n  The company is also seeing strong uptake for Ekterly in Germany, Palleiko said, noting early prescribing behaviors in the country have mirrored the positive trends the company saw in the U.S. The company expects to expand into other major markets this year, he added. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2026 18:53 ET (23:53 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}